Cite
Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine.
MLA
Zhang, Ping-Ping, et al. “Differentiation Therapy of Hepatocellular Carcinoma by Inhibiting the Activity of AKT/GSK-3β/β-Catenin Axis and TGF-β Induced EMT with Sophocarpine.” Cancer Letters, vol. 376, no. 1, June 2016, pp. 95–103. EBSCOhost, https://doi.org/10.1016/j.canlet.2016.01.011.
APA
Zhang, P.-P., Wang, P.-Q., Qiao, C.-P., Zhang, Q., Zhang, J.-P., Chen, F., Zhang, X., Xie, W.-F., Yuan, Z.-L., Li, Z.-S., & Chen, Y.-X. (2016). Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine. Cancer Letters, 376(1), 95–103. https://doi.org/10.1016/j.canlet.2016.01.011
Chicago
Zhang, Ping-Ping, Pei-Qin Wang, Chun-Ping Qiao, Qing Zhang, Jun-Ping Zhang, Fei Chen, Xin Zhang, et al. 2016. “Differentiation Therapy of Hepatocellular Carcinoma by Inhibiting the Activity of AKT/GSK-3β/β-Catenin Axis and TGF-β Induced EMT with Sophocarpine.” Cancer Letters 376 (1): 95–103. doi:10.1016/j.canlet.2016.01.011.